Raltegravir — CAS 518048-05-0

Raltegravir is the first approved HIV integrase strand transfer inhibitor (INSTI), blocking the integration of HIV-1 DNA into the human genome. It is a key component of combination antiretroviral therapy for HIV-1 infection. Mediocon Inc manufactures GMP-compliant Raltegravir at its Aurangabad facility.

• HIV-1 infection treatment (antiretroviral therapy)
• HIV integrase strand transfer inhibitor
• Combination antiretroviral therapy (cART)
• Prevention of HIV DNA integration into host genome

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support